NCT01494441

Brief Summary

The purpose of this pilot clinical trial is to evaluate both device designs (rhBMP-2/BCP and rhBMP-2/BCP/TSRH® spinal System) as methods of facilitating spinal fusion as compared to instrumented fusion with autograft in patients with symptomatic degenerative disc disease.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 1999

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 1999

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2003

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2003

Completed
8.8 years until next milestone

First Submitted

Initial submission to the registry

December 12, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 19, 2011

Completed
Last Updated

May 17, 2023

Status Verified

May 1, 2023

Enrollment Period

3.8 years

First QC Date

December 12, 2011

Last Update Submit

May 16, 2023

Conditions

Keywords

lumbar degenerative disc disease

Outcome Measures

Primary Outcomes (2)

  • Fusion

    Fusion is defined as: 1. Evidence of bridging trabecular bone. 2. No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs; 3. Absence of radiolucent lines completely through the fusion mass.

    24 month

  • Pain/Disability Status

    The self-administered Oswestry Low Back pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score \>= 15

    24 month

Secondary Outcomes (7)

  • Neurological Status Success

    24 month

  • Hip (Donor Site) Pain

    24 month

  • General Health Status (SF-36)

    24 month

  • Pain Status (back pain, leg pain)

    24 month

  • Patient Satisfaction

    24 month

  • +2 more secondary outcomes

Study Arms (3)

rhBMP-2/BCP

EXPERIMENTAL
Procedure: rhBMP-2/BCP

rhBMP-2/BCP/TSRH® Spinal System

EXPERIMENTAL
Device: rhBMP-2/BCP/TSRH® Spinal System

Autograft/TSRH® Spinal System

ACTIVE COMPARATOR
Device: Autograft/TSRH® Spinal System

Interventions

rhBMP-2/BCPPROCEDURE

The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.

Also known as: recombinant human Bone Morphogenetic Protein-2, biphasic calcium phosphate
rhBMP-2/BCP

rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.

Also known as: recombinant human Bone Morphogenetic Protein-2, biphasic calcium phosphate
rhBMP-2/BCP/TSRH® Spinal System

The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.

Also known as: Autograft
Autograft/TSRH® Spinal System

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain \[leg, back, or symptoms in the sciatic nerve distribution\] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include one or more of the following:
  • instability (defined as angular motion \> 5° and/or translation \> 4 mm, based on Flex/Ext radiographs);
  • osteophyte formation;
  • decreased disc height;
  • thickening of ligamentous tissue;
  • disc degeneration or herniation; and/or
  • facet joint degeneration.
  • Has preoperative Oswestry score \> 30.
  • Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).
  • Requires fusion of a single level disc space from L1 to S1.
  • Is at least 18 years of age, inclusive, at the time of surgery.
  • Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
  • If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
  • Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

You may not qualify if:

  • Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.
  • Had previous spinal fusion surgical procedure at the involved level.
  • Require spinal fusion at more than one lumbar level.
  • Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
  • Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
  • Has presence of active malignancy.
  • Has overt or active bacterial infection, either local or systemic.
  • Is grossly obese, i.e., weight \> 40% over ideal for their age and height.
  • Has fever ( temperature \>101°F oral) at the time of surgery.
  • Has a documented titanium alloy allergy or intolerance.
  • Is mentally incompetent. If questionable, obtain psychiatric consult.
  • Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
  • Is a prisoner.
  • Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
  • Is a tobacco user at the time of surgery.
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Intervertebral Disc Degeneration

Interventions

recombinant human bone morphogenetic protein-2hydroxyapatite-beta tricalcium phosphateTransplantation, Autologous

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

TransplantationSurgical Procedures, Operative

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 12, 2011

First Posted

December 19, 2011

Study Start

May 1, 1999

Primary Completion

March 1, 2003

Study Completion

March 1, 2003

Last Updated

May 17, 2023

Record last verified: 2023-05